Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Hypoxia-induced adenosine creates an immunosuppressive tumor microenvironment (TME) and dampens the efficacy of immune checkpoint inhibitors (ICIs). We found that hypoxia-inducible factor 1 (HIF-1) orchestrates adenosine efflux through two steps in hepatocellular carcinoma (HCC). First, HIF-1 activates transcriptional repressor MXI1, which inhibits adenosine kinase (ADK), resulting in the failure of adenosine phosphorylation to adenosine monophosphate. This leads to adenosine accumulation in hypoxic cancer cells. Second, HIF-1 transcriptionally activates equilibrative nucleoside transporter 4, pumping adenosine into the interstitial space of HCC, elevating extracellular adenosine levels. Multiple in vitro assays demonstrated the immunosuppressive role of adenosine on T cells and myeloid cells. Knockout of ADK in vivo skewed intratumoral immune cells to protumorigenic and promoted tumor progression. Therapeutically, combination treatment of adenosine receptor antagonists and anti–PD-1 prolonged survival of HCC-bearing mice. We illustrated the dual role of hypoxia in establishing an adenosine-mediated immunosuppressive TME and offered a potential therapeutic approach that synergizes with ICIs in HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3. Adenosine promotes Treg differentiation and cell death while suppressing T cell proliferation and functions. (A) CellTrace Violet (CTV) T cell proliferation assay on (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA (adenosine stable analog) for 3 days with IL-2. (B) Percentages of (left) IFN-γ+ and (right) granzyme B+ CD8+ T cells treated with indicated doses of NECA for 3 days with IL-2. (C) Percentage of cell death of (left) CD8+ and (right) CD4+ T cells treated with indicated doses of NECA for 3 days with IL-2. (D) Splenic T cells were cultured with 100 μM NECA in the presence of vehicle [dimethyl sulfoxide (DMSO)], 100 nM A2AR antagonist (ZM241385), or 100 nM A2BR antagonist (CVT6883) for 3 days with IL-2. The percentage of Tregs (CD4+ CD25+FOXP3+) was determined by flow cytometry. (E to H) Bulk RNA sequencing was performed on NECA-treated T cells compared to vehicle (DMSO). (E) to (G) GSEA showed the enrichment of selected gene sets in NECA-treated T cells. (H) Fold change of selected genes as compared to vehicle. Error bars indicate means ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 versus 0 μM or DMSO as indicated. Student’s t test. ns, not significant.](https://figures.cochat.ai/paper-figures/0d68e93bfa9e4ed29df3e2a43cc9adad/hypoxia-inducible-factor-orchestrates-adenosine-metabolism-to-promote-liver-figure-3.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Inhibition of either ENTPD2 or ADK enhanced the activity of immune checkpoint inhibitors, which highlights their significance in driving immunosuppression and their potential utility as therapeutic targets to enhance the efficacy of immune checkpoint inhibitors [90, 93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, HIF activates transcriptional repressor MXI1, which inhibits ADK, resulting in adenosine accumulation in hypoxic cancer cells [93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
The cited source says what the claim attributes to it.
In the citing paper
“The HIFs also transcriptionally activate ENT4, which pumps adenosine into the interstitial space, elevating extracellular adenosine levels, which is associated with immunosuppressive effects [93].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [93]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Wang, G. L., Jiang, B. H., Rue, E. A., & Semenza, G. L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.12.5510 · Cited by 6,212
Understanding the tumor immune microenvironment (TIME) for effective therapy
Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Hypoxia induces transcriptional activation of multiple genes involved in tumor development including cancer cell proliferation, angiogenesis, and migration ( 46 ).”
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645 · cited 1×
“HIF comprises an O 2 -re- sponsive HIF-1/2α subunit and a constitutively expressed HIF-1β subunit ( 10 ).”
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333 · cited 1×
“In the presence of O 2 (normoxia), HIF-1/2α is hydroxylated by prolyl hydroxylase ( 11 ), permitting E3 ubiquitin ligase von Hippel – Lindau protein (VHL) to bind to HIF-1/2α and mediate the proteasomal degradation of HIF-1/2α ( 12 ).”
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251 · cited 1×
“In the presence of O 2 (normoxia), HIF-1/2α is hydroxylated by prolyl hydroxylase ( 11 ), permitting E3 ubiquitin ligase von Hippel – Lindau protein (VHL) to bind to HIF-1/2α and mediate the proteasomal degradation of HIF-1/2α ( 12 ).”
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 1×
“T reg also expresses CD39, which, together with CD73 expressed on cancer cells and other stromal cells, produces adenosine to inhibit T cells and NK cells ( 23 – 25 ).”
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma
Zhang, Q., He, Y., Luo, N., Patel, S. J., Han, Y., Gao, R., Modak, M., Carotta, S., Haslinger, C., Kind, D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.003 · Cited by 1,624
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Jiang, X., Wang, J., Deng, X., Xiong, F., Ge, J., Xiang, B., Wu, X., Ma, J., Zhou, M., Li, X., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-018-0928-4 · Cited by 1,457 · cited 1×
“TME is a complexed and interactive network with multiple components including cancer cells, immune cells, stromal cells, extracellular matrix, and vasculature ( 6 , 7 ).”
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“Extracellular adenosine exerts its immunosuppressive effect via interacting with four heterotrimeric guanine nucleotide-binding protein – coupled receptors [adesonsine A1 receptor (A1R), adenosine 2A receptor (A2AR), adenosine 2B receptor (A2BR), and A3R] ( 21 ).”
Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
A2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065
Genomic targets of the human c-Myc protein
Fernandez, P. C., Frank, S. R., Wang, L., Schroeder, M., Liu, S., Greene, J., Cocito, A., & Amati, B. (2003) · Genes & Development · doi:10.1101/gad.1067003 · Cited by 973 · cited 1×
“Under hypoxia, MXI1 is up-regulated and functions as a transcription repressor by competing with MYC to dimerize with MAX and bind to E-box element (5 ′ -CACGTG-3 ′ ) at gene promoter region ( 36 ), thereby preventing the transcriptional activation mediated by MYC binding.”
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Cheng, P., Corzo, C. A., Luetteke, N., Yu, B., Nagaraj, S., Bui, M. M., Ortiz, M., Nacken, W., Sorg, C., Vogl, T., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080132 · Cited by 902
Zhang, H., Gao, P., Fukuda, R., Kumar, G., Krishnamachary, B., Zeller, K. I., Dang, C. V., & Semenza, G. L. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.001 · Cited by 885 · cited 2×
“This is consistent with a previous study demonstrating that MXI1 was induced under hypoxia and suppressed MYC activities ( 35 ).”
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Proinflammatory S100 Proteins Regulate the Accumulation of Myeloid-Derived Suppressor Cells
Sinha, P., Okoro, C., Foell, D., Freeze, H. H., Ostrand-Rosenberg, S., & Srikrishna, G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.7.4666 · Cited by 725
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679 · cited 1×
“HIF also induces the production of immunosuppressive metabolites such as adenosine through transcriptionally activating the ectoenzymes CD39/ CD39L1 and CD73 ( 17 – 19 ).”
Synnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Mole, D. R., Blancher, C., Copley, R. R., Pollard, P. J., Gleadle, J. M., Ragoussis, J., & Ratcliffe, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m901790200 · Cited by 552 · cited 1×
“While most of the studies focused on the hypoxia-induced gene activation, a significant number of genes are suppressed by hypoxia, which is HIF-1 dependent in an indirect manner ( 47 , 48 ).”
Chiu, D. K.-C., Tse, A. P.-W., Xu, I. M.-J., Di Cui, J., Lai, R. K.-H., Li, L. L., Koh, H.-Y., Tsang, F. H.-C., Wei, L. L., Wong, C.-M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00530-7 · Cited by 448
Self-citationHypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation
Wong, C. C.-L., Gilkes, D. M., Zhang, H., Chen, J., Wei, H., Chaturvedi, P., Fraley, S. I., Wong, C.-M., Khoo, U.-S., Ng, I. O.-L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1113483108 · Cited by 437 · cited 1×
“For HIF-1 β knockdown HCC cell lines, short hairpin RNAs (shRNAs) targeting HIF-1 β, or nontargeting control was inserted into pLKO.1-puro vectors and was stably transfected into MHCC97L and CLC11 cells ( 58 ), followed by puromycin selection.”
Self-citationAdenosine receptors in regulation of dendritic cell differentiation and function
Novitskiy, S. V., Ryzhov, S., Zaynagetdinov, R., Goldstein, A. E., Huang, Y., Tikhomirov, O. Y., Blackburn, M. R., Biaggioni, I., Carbone, D. P., Feoktistov, I., et al. (2008) · Blood · doi:10.1182/blood-2008-02-136325 · Cited by 430
Perrot, I., Michaud, H.-A., Giraudon-Paoli, M., Augier, S., Docquier, A., Gros, L., Courtois, R., Déjou, C., Jecko, D., Becquart, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.04.091 · Cited by 423 · cited 1×
“CD39 and CD73 have been hotly pursued therapeutic targets in treating cancers ( 28 , 29 ).”
Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420
Krishnamachary, B., Zagzag, D., Nagasawa, H., Rainey, K., Okuyama, H., Baek, J. H., & Semenza, G. L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3719 · Cited by 415 · cited 1×
“For example, hypoxia induced transcription factor 3 (TCF3), zinc finger homeobox protein 1A (ZFHX1A), and ZFHX1B, resulting in the down-regulation of E-cadherin in hypoxic cells, reducing cell-cell adhesion ( 49 ).”
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
Stagg, J., Divisekera, U., Duret, H., Sparwasser, T., Teng, M. W. L., Darcy, P. K., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4246 · Cited by 401
Ohta, A., Kini, R., Ohta, A., Subramanian, M., Madasu, M., & Sitkovsky, M. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00190 · Cited by 398
The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29
Young, J. D., Yao, S. Y. M., Baldwin, J. M., Cass, C. E., & Baldwin, S. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.05.007 · Cited by 356 · cited 2×
“ENT4 is more divergent from ENT1 to ENT3, and it is only specific to adenosine, while ENT1 to ENT3 members have affinities for other nucleosides ( 30 ).”
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
Beavis, P. A., Divisekera, U., Paget, C., Chow, M. T., John, L. B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M. J., & Darcy, P. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308209110 · Cited by 345
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
Adenosine Metabolism: Emerging Concepts for Cancer Therapy
Boison, D., & Yegutkin, G. G. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.007 · Cited by 336
Immunobiology and immunotherapy of HCC: spotlight on innate and innate-like immune cells
Ruf, B., Heinrich, B., & Greten, T. F. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00572-w · Cited by 312
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
Ryzhov, S., Novitskiy, S. V., Goldstein, A. E., Biktasova, A., Blackburn, M. R., Biaggioni, I., Dikov, M. M., & Feoktistov, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101225 · Cited by 261
Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
Eltzschig, H. K., Köhler, D., Eckle, T., Kong, T., Robson, S. C., & Colgan, S. P. (2009) · Blood · doi:10.1182/blood-2008-06-165746 · Cited by 244
Chiu, D. K., Xu, I. M., Lai, R. K., Tse, A. P., Wei, L. L., Koh, H., Li, L. L., Lee, D., Lo, R. C., Wong, C., et al. (2016) · Hepatology · doi:10.1002/hep.28655 · Cited by 241
Self-citationTargeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?
Fei, L., Ren, X., Yu, H., & Zhan, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771210 · Cited by 219
Ohta, A., Ohta, A., Madasu, M., Kini, R., Subramanian, M., Goel, N., & Sitkovsky, M. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901247 · Cited by 215
HIF-1–dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak
Morote-Garcia, J. C., Rosenberger, P., Kuhlicke, J., & Eltzschig, H. K. (2008) · Blood · doi:10.1182/blood-2007-11-126763 · Cited by 210
Barnes, K., Dobrzynski, H., Foppolo, S., Beal, P. R., Ismat, F., Scullion, E. R., Sun, L., Tellez, J., Ritzel, M. W. L., Claycomb, W. C., et al. (2006) · Circulation Research · doi:10.1161/01.res.0000238359.18495.42 · Cited by 196 · cited 1×
“ENT4 has been reported to regulate the level of extracellular adenosine in heart under acidic condition ( 32 ).”
Kung-Chun Chiu, D., Pui-Wah Tse, A., Law, C.-T., Ming-Jing Xu, I., Lee, D., Chen, M., Kit-Ho Lai, R., Wai-Hin Yuen, V., Wing-Sum Cheu, J., Wai-Hung Ho, D., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2155-3 · Cited by 192
Self-citationLeone, R. D., Sun, I.-M., Oh, M.-H., Sun, I.-H., Wen, J., Englert, J., & Powell, J. D. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2186-0 · Cited by 190 · cited 1×
“It demonstrated antitumor efficacy and worked synergistically with ICIs in preclinical models ( 56 ).”
Gs Protein-Coupled Adenosine Receptor Signaling and Lytic Function of Activated NK Cells
Raskovalova, T., Huang, X., Sitkovsky, M., Zacharia, L. C., Jackson, E. K., & Gorelik, E. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.7.4383 · Cited by 175 · cited 1×
“T reg also expresses CD39, which, together with CD73 expressed on cancer cells and other stromal cells, produces adenosine to inhibit T cells and NK cells ( 23 – 25 ).”
Huang, G., 杨连粤, & Lu, W.-Q. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i11.1705 · Cited by 163
Iannone, R., Miele, L., Maiolino, P., Pinto, A., & Morello, S. (2013) · Neoplasia · doi:10.1593/neo.131748 · Cited by 152
Ng, I. O. L., Lai, E. C. S., Fan, S. T., Ng, M. M. T., & So, M. K. P. (1995) · Cancer · doi:10.1002/1097-0142(19951215)76:12<2443::aid-cncr2820761207>3.0.co;2-f · Cited by 152 · cited 1×
“The expression level of ENT4 in patients with HCC was correlated with multiple clinicopathological parameters (tumor microsatellite formation, direction liver invasion, tumor encapsulation, venous invasion, tumor stage, tumor size, and Edmondson grading) using SPSS 20.0 software as described ( 57 ).”
InfluentialSelf-citationThe SIN3A histone deacetylase complex is required for a complete transcriptional response to hypoxia
Tiana, M., Acosta‐Iborra, B., Puente-Santamaría, L., Hernansanz‐Agustín, P., Worsley-Hunt, R., Masson, N., Rio, F. G., Mole, D. R., Ratcliffe, P. J., Wasserman, W. W., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx951 · Cited by 138 · cited 1×
“…multiple components of the SIN3 transcription regulator family member A (SIN3A) histone deacetylase (HDAC) co-repressor complex together with MXI1 at hypoxia-sup-pressed genes and suggested that MXI1 interacted with SIN3A/ HDAC co-repressor complex to mediate gene suppression under hypoxia ( 51 ).”
The SLC28 (CNT) and SLC29 (ENT) nucleoside transporter families: a 30-year collaborative odyssey
Young, J. D. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160038 · Cited by 110 · cited 1×
“ENT4 is exclusively found in the plasma membrane ( 31 ).”
Häusler, S. F., del Barrio, I. M., Diessner, J., Stein, R. G., Strohschein, J., Hönig, A., Dietl, J., & Wischhusen, J. (2014) · Europe PMC (PubMed Central) · Cited by 109
Bagga, D., Ashley, J. M., Geffrey, S. P., Wang, H.-J., Barnard, R. J., Korenman, S. G., & Heber, D. (1995) · Cancer · doi:10.1002/1097-0142(19951215)76:12<2565::aid-cncr2820761224>3.0.co;2-b · Cited by 104
Self-citationLi, H., Smolen, G. A., Beers, L. F., Li, X., Gerald, W. L., Wang, J., Haber, D. A., & Lee, S. B. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002353 · Cited by 54 · cited 1×
“ENT4 was reported to be up-regulated in desmoplastic small round cell tumor (DSRCT) ( 45 ).”
Dysregulation of adenosine kinase isoforms in breast cancer
Shamloo, B., Kumar, N., Owen, R., Reemmer, J., Ost, J. A., Perkins, R. S., & Shen, H. (2019) · Oncotarget · doi:10.18632/oncotarget.27364 · Cited by 19
Adenosine Kinase Deficiency Increases Susceptibility to a Carcinogen
El-Kharrag, R., Owen, R., & Boison, D. (2019) · Journal of Caffeine and Adenosine Research · doi:10.1089/caff.2018.0019 · Cited by 16
Cited by
Metabolic reprogramming in the tumor microenvironment of liver cancer
Lin, J., Rao, D., Zhang, M., & Gao, Q. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01527-8 · Cited by 251
“This results in adenosine-mediated immunosuppressive roles on T cells and myeloid cells [149, 150].”
BackgroundSelf-citationYin, Y., Feng, W., Chen, J., Chen, X., Wang, G., Wang, S., Xu, X., Nie, Y., Fan, D., Wu, K., et al. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00539-x · Cited by 137
Nanocatalysts for modulating antitumor immunity: fabrication, mechanisms and applications
Wu, X., Li, Y., Wen, M., Xie, Y., Zeng, K., Liu, Y., Chen, W., & Zhao, Y. (2024) · Chemical Society Reviews · doi:10.1039/d3cs00673e · Cited by 99
Immunometabolism: crosstalk with tumor metabolism and implications for cancer immunotherapy
Zhang, H., Fan, J., Kong, D., Sun, Y., Zhang, Q., Xiang, R., Lu, S., Yang, W., Feng, L., & Zhang, H. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02460-1 · Cited by 58
The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation
Acuña-Pilarte, K., & Koh, M. Y. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.06.005 · Cited by 64
Metadata
- Authors
- Cheu, J. W.-S., Chiu, D. K.-C., Kwan, K. K.-L., Yang, C., Yuen, V. W.-H., Goh, C. C., Chui, N. N.-Q., Shen, W., Law, C.-T., Li, Q., Zhang, M. S., Bao, M. H.-R., Wong, B. P.-Y., Chan, C. Y.-K., Liu, C. X., Sit, G. F.-W., Ooi, Z. Y., Deng, H., Tse, A. P.-W., Ng, I. O.-L., & Wong, C. C.-L.
- Affiliations
- University of Hong Kong (HK)
- Sun Yat-sen University (CN)
- Corresponding author
- Wong, Carmen Chak-Lui
- ORCID
- Venue
- Science Advances
- Published
- 2023-05-05
- Volume
- 9
- Issue
- 18
- Pages
- eade5111-eade5111
- ISSN
- 2375-2548 (ISSN-L)
- PMC
- PMC10162666
- OpenAlex
- W4372332351
- Cited by
- 65
- References
- 61
- Citations by year
- 2026: 20 · 2025: 24 · 2024: 20 · 2023: 1
- FWCI
- 12.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- Science Advances (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (82022077)
- University of Hong Kong
- Directorate for Biological Sciences
- Cornell Center for Materials Research
- Young Scientists Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- HIF-1, hepatocellular carcinoma, adenosine metabolism, adenosine kinase, MXI1, immunosuppressive tumor microenvironment, adenosine receptor antagonists, anti-PD-1 combination therapy, immune checkpoint inhibitors, tumor hypoxia
- MeSH terms
- Adenosine, Animals, Hypoxia, Carcinoma, Hepatocellular, Liver Neoplasms, Mice, Knockout, Cell Line, Tumor, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.